Advertisement

Venous Thromboembolism in Older Adults: A Community-based Study

Published:February 19, 2014DOI:https://doi.org/10.1016/j.amjmed.2014.02.011

      Abstract

      Background

      While the incidence of venous thromboembolism increases with age, little is known about its contemporary management or outcomes in older patients. Our goal was to compare the characteristics, treatment, and outcomes associated with venous thromboembolism, in patients aged 65-69 years, 70-74 years, 75-79 years, and 80+ years.

      Methods/Participants

      We prospectively followed 542 subjects aged ≥65 years with venous thromboembolism from January 2008 through August 2011 at 6 sites. In addition, a retrospective study of 681 additional subjects aged ≥65 years with venous thromboembolism diagnosed in 2007 and 2009 was conducted at the same 6 sites.

      Results

      With advancing age, patients were more likely to suffer provoked venous thromboembolism but less likely to present with pulmonary embolism. Patients with unprovoked, provoked, or malignancy-associated venous thromboembolism received warfarin for a median of 401 days, 203 days, and 529 days, respectively. Age ≥80 years was not associated with an increased risk of recurrent venous thromboembolism, but there was an increased risk of all-cause mortality.

      Conclusion

      With advancing age, patients are more likely to suffer hospital-associated and provoked venous thromboembolism. Many elderly patients with provoked or unprovoked venous thromboembolism were treated for >3 months or >12 months, respectively. Given that advanced age was not associated with increased risk of recurrent venous thromboembolism, but elderly patients in general have a higher risk of bleeding from continued anticoagulant therapy, such practice is potentially harmful. At the same time, such an argument could be used to more vigorously offer prophylaxis in the first place.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Spencer F.A.
        • Emery C.
        • Joffe S.W.
        • et al.
        Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study.
        J Thromb Thrombolysis. 2009; 28: 401-409
        • Spencer F.A.
        • Emery C.
        • Lessard D.
        • et al.
        The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.
        J Gen Intern Med. 2006; 21: 722-727
        • Carrier M.
        • Righini M.
        • Wells P.S.
        • et al.
        Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies.
        J Thromb Haemost. 2010; 8: 1716-1722
        • Schulman S.
        • Kearon C.
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Spencer F.A.
        • Gore J.M.
        • Lessard D.
        • et al.
        Venous thromboembolism in the elderly. A community-based perspective.
        Thromb Haemost. 2008; 100: 780-788
        • Engbers M.J.
        • van Hylckama Vlieg A.
        • Rosendaal F.R.
        Venous thrombosis in the elderly: incidence, risk factors and risk groups.
        J Thromb Haemost. 2010; 8: 2105-2112
        • Kearon C.
        • Akl E.A.
        • Comerota A.J.
        • et al.
        Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: e419S-e494S
        • Anderson Jr., F.A.
        • Wheeler H.B.
        • Goldberg R.J.
        • et al.
        A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.
        Arch Intern Med. 1991; 151: 933-938
        • Heit J.A.
        • Silverstein M.D.
        • Mohr D.N.
        • et al.
        The epidemiology of venous thromboembolism in the community.
        Thromb Haemost. 2001; 86: 452-463
        • Heit J.A.
        • Mohr D.N.
        • Silverstein M.D.
        • Petterson T.M.
        • O'Fallon W.M.
        • Melton 3rd, L.J.
        Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.
        Arch Intern Med. 2000; 160: 761-768
        • White R.H.
        • Zhou H.
        • Romano P.S.
        Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism.
        Arch Intern Med. 1998; 158: 1005-1010
      1. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
        Arch Intern Med. 1996; 156: 409-416
        • Campbell N.R.
        • Hull R.D.
        • Brant R.
        • Hogan D.B.
        • Pineo G.F.
        • Raskob G.E.
        Aging and heparin-related bleeding.
        Arch Intern Med. 1996; 156: 857-860
        • Hylek E.M.
        • Evans-Molina C.
        • Shea C.
        • Henault L.E.
        • Regan S.
        Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
        Circulation. 2007; 115: 2689-2696
        • Kuijer P.M.
        • Hutten B.A.
        • Prins M.H.
        • Buller H.R.
        Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.
        Arch Intern Med. 1999; 159: 457-460
        • Pengo V.
        Oral anticoagulant treatment in very elderly patients with atrial fibrillation.
        Compr Ther. 2001; 27: 7-10
        • Vasco B.
        • Villalba J.C.
        • Lopez-Jimenez L.
        • et al.
        Venous thromboembolism in nonagenarians. Findings from the RIETE Registry.
        Thromb Haemost. 2009; 101: 1112-1118